The scientist’s investigation covers issues in Internal medicine, Cancer, Melanoma, Clinical trial and Gastroenterology. His biological study spans a wide range of topics, including Placebo, Gynecology, Surgery and Oncology. Frank L. Meyskens is interested in Cancer prevention, which is a branch of Cancer.
He works mostly in the field of Cancer prevention, limiting it down to topics relating to Lung cancer and, in certain cases, Epidemiology and Relative risk, as a part of the same area of interest. The concepts of his Melanoma study are interwoven with issues in Molecular biology, In vitro, Karyotype and Transcription factor. His biological study spans a wide range of topics, including Oral administration, Adverse effect, Taxane and Confidence interval.
His scientific interests lie mostly in Internal medicine, Melanoma, Cancer, Cancer research and Oncology. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Placebo and Endocrinology. His Melanoma research incorporates elements of Molecular biology, Cell culture, Immunology and Pathology.
His Molecular biology study combines topics from a wide range of disciplines, such as Cell and Clonogenic assay. Cancer connects with themes related to Surgery in his study. His Oncology study integrates concerns from other disciplines, such as Breast cancer, Disease and Chemotherapy.
Frank L. Meyskens mainly focuses on Internal medicine, Melanoma, Cancer research, Oncology and Cancer. His Internal medicine research incorporates themes from Gastroenterology and Placebo. The various areas that Frank L. Meyskens examines in his Melanoma study include Reactive oxygen species, Epidemiology, Immunology and Skin cancer.
His Cancer research research includes elements of Cell culture, Gene knockdown and Kinase, MAPK/ERK pathway. His studies in Cancer integrate themes in fields like Aspirin, Asymptomatic and Disease. His Cancer prevention research is multidisciplinary, relying on both Gerontology and Family medicine.
Frank L. Meyskens spends much of his time researching Internal medicine, Cancer, Oncology, Gastroenterology and Melanoma. His research integrates issues of Placebo and Surgery in his study of Internal medicine. His study in Cancer is interdisciplinary in nature, drawing from both Aspirin and Gerontology.
His research in Gastroenterology intersects with topics in Endocrinology, Hazard ratio, Confidence interval, Proportional hazards model and Vitamin E. His Melanoma study combines topics in areas such as Metastasis, Epidemiology, Immunology and Skin cancer. His Cancer prevention research includes themes of Precision medicine and Comparative effectiveness research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EFFECTS OF A COMBINATION OF BETA CAROTENE AND VITAMIN A ON LUNG CANCER AND CARDIOVASCULAR DISEASE
Gilbert S. Omenn;Gary E. Goodman;Gary E. Goodman;Mark D. Thornquist;John Balmes.
The New England Journal of Medicine (1996)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Scott M. Lippman;Eric A. Klein;Eric A. Klein;Phyllis J. Goodman;M. Scott Lucia.
Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein;Ian M. Thompson;Catherine M. Tangen;John J. Crowley.
Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy Trial
Gilbert S. Omenn;Gary E. Goodman;Mark D. Thornquist;John Balmes.
Journal of the National Cancer Institute (1996)
Polyamines and cancer: old molecules, new understanding
Eugene W. Gerner;Frank L. Meyskens.
Nature Reviews Cancer (2004)
Reactive Oxygen Species: A Breath of Life or Death?
John P. Fruehauf;Frank L. Meyskens.
Clinical Cancer Research (2007)
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
Jack Cuzick;Florian Otto;Florian Otto;John A Baron;Powel H Brown.
Lancet Oncology (2009)
Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma
Lowell A. Goldsmith;Frederic B. Askin;Alfred E. Chang;Cynthia Cohen.
Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Frank L. Meyskens;Eugene W. Gerner.
Clinical Cancer Research (1999)
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Halle C F Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle.
The New England Journal of Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: